```html

Zollinger‑Like Gastric Hypersecretion

Overview

Zollinger‑like gastric hypersecretion (ZLGH) is a rare condition in which the stomach produces excessive amounts of gastric acid, mimicking the acid‑overproduction seen in Zollinger‑Ellison syndrome (ZES) but without an identifiable gastrin‑producing tumor (gastrinoma). The excess acid can lead to severe peptic ulcer disease, gastro‑esophageal reflux, and malabsorption.

Although the exact prevalence is not well defined, studies estimate that 0.5–1.5 per 100,000 adults develop ZLGH. It most often presents in middle‑aged adults (40–65 years) and has a slight male predominance (approximately 55 % of cases).

Because the condition is uncommon and the symptoms overlap with many other gastrointestinal (GI) disorders, it is frequently misdiagnosed or discovered only after complications develop.

Symptoms

Patients with ZLGH experience a spectrum of symptoms related to chronic acid irritation and ulcer formation. The following list includes the most common complaints, along with brief explanations.

Upper‑Abdominal Pain

• Epigastric burning or gnawing pain that may improve with food (typical of duodenal ulcer) or worsen after meals (gastric ulcer).
• Pain is often described as “sharp” or “cramping” and can radiate to the back.

Heartburn & Gastro‑esophageal Reflux Disease (GERD)

• Acid reflux causing a sour taste, chest discomfort, or a burning sensation behind the breastbone.
• May be chronic and refractory to over‑the‑counter antacids.

Peptic Ulcer Disease (PUD)

• Multiple or recurrent ulcers in the stomach or duodenum, often seen on endoscopy.
• Ulcers may bleed, leading to melena (dark stools) or hematemesis (vomiting blood).

Diarrhea & Steatorrhea

• Excess acid inactivates pancreatic enzymes and damages the mucosa, causing fat malabsorption and oily, foul‑smelling stools.

Weight Loss

• Resulting from chronic pain, malabsorption, or decreased appetite.

Nausea & Vomiting

• Often triggered by ulcer pain or gastric outlet obstruction.

Bitterness in the Mouth

• Acid reflux can produce a metallic or bitter taste, especially after meals.

Extra‑intestinal Signs (rare)

• Fatigue, anemia (from chronic blood loss), and osteoporosis (due to impaired calcium absorption).

Causes and Risk Factors

Unlike classic ZES, ZLGH does not involve a gastrin‑producing tumor. The pathogenesis is thought to involve a combination of the following mechanisms:

• Hypergastrinemia of non‑neoplastic origin – elevated gastrin levels due to chronic atrophic gastritis or H. pylori infection can stimulate acid‑producing parietal cells.
• Genetic predisposition – rare familial variants affecting the ATP4A gene (encoding the gastric H⁺/K⁺‑ATPase) have been reported.
• Autoimmune gastritis – leads to loss of somatostatin‑producing D cells, removing the brake on gastrin release.
• Medication‑induced rebound hypersecretion – prolonged use of proton‑pump inhibitors (PPIs) can cause compensatory hypergastrinemia after abrupt discontinuation.

Risk Factors

• Age > 40 years.
• Male sex (slight predominance).
• Chronic H. pylori infection or prior eradication therapy.
• Long‑term PPI use (> 1 year) without gradual taper.
• Family history of gastrin‑related disorders.
• Autoimmune diseases (e.g., Hashimoto thyroiditis, type 1 diabetes) that increase the likelihood of autoimmune gastritis.

Diagnosis

Because ZLGH mimics many other GI conditions, a systematic approach is essential.

1. Clinical Evaluation

• Detailed history focusing on ulcer recurrence, medication use, and family history.
• Physical examination for signs of anemia, abdominal tenderness, or abdominal masses.

2. Laboratory Tests

• Fasting serum gastrin – typically elevated (> 100 pg/mL) but < 1,000 pg/mL (distinguishes from ZES where levels often exceed 1,000 pg/mL).
• Secretin stimulation test – used to rule out gastrinoma; in ZLGH, gastrin does not rise markedly after secretin.
• Complete blood count (CBC) – to detect anemia.
• Serum calcium & vitamin D – assess for secondary metabolic bone disease.
• H. pylori testing (urea breath test, stool antigen, or biopsy).

3. Endoscopic Evaluation

• Upper endoscopy (EGD) – visualizes ulcers, assesses gastric mucosa, and allows biopsies for H. pylori, atrophic gastritis, or intestinal metaplasia.
• Biopsies are also sent for immunohistochemistry to exclude neuroendocrine tumors.

4. Imaging Studies

• CT or MRI abdomen – performed when a gastrinoma is still suspected despite negative secretin test.
• Somatostatin receptor scintigraphy (Octreoscan) or Ga‑68 DOTATATE PET/CT – highly sensitive for gastrinomas but generally negative in ZLGH.

5. pH Monitoring

• 24‑hour intra‑gastric pH monitoring confirms persistent low pH (< 2) consistent with hypersecretion.

Diagnosis of ZLGH is made when:

1. Acid hypersecretion is documented.
2. Serum gastrin is moderately elevated without a secretin‑responsive gastrinoma.
3. Imaging fails to reveal a tumor.
4. Other causes (e.g., H. pylori, NSAID use) have been ruled out or treated.

Treatment Options

Therapeutic goals are to suppress gastric acid, heal existing ulcers, prevent recurrence, and address underlying contributors.

1. Acid‑Suppressive Medications

• Proton‑pump inhibitors (PPIs) – the cornerstone of therapy. High‑dose regimens (e.g., omeprazole 40 mg twice daily) are often required initially.
• Histamine‑2 receptor antagonists (H2RAs) – may be added for breakthrough symptoms, but tolerance can develop.
• Potassium‑competitive acid blockers (P‑CABs) – e.g., vonoprazan (available in some countries) provide rapid, potent acid suppression and may be useful in refractory cases.

2. Treat Underlying Causes

• Eradicate H. pylori infection with a standard triple or quadruple regimen (clarithromycin‑based or bismuth‑based therapy).
• If autoimmune gastritis is identified, monitor for pernicious anemia and replace vitamin B12 as needed.
• Gradually taper long‑term PPI use to avoid rebound hypergastrinemia.

3. Surgical & Endoscopic Interventions

• Endoscopic ulcer therapy – argon plasma coagulation or clipping for actively bleeding ulcers.
• Partial gastrectomy – rarely performed; considered only when medical therapy fails and ulcer complications (perforation, refractory bleeding) persist.

4. Adjunctive Therapies

• Sucralfate – mucosal protective coating that can aid ulcer healing.
• Pancreatic enzyme supplements – for patients with steatorrhea due to acid inactivation of enzymes.
• Bone health management – calcium, vitamin D, and possibly bisphosphonates if osteopenia/osteoporosis develops.

5. Lifestyle Modifications

• Avoid NSAIDs, aspirin, and other ulcerogenic drugs unless essential.
• Limit alcohol and caffeine, which can stimulate acid secretion.
• Eat smaller, more frequent meals rather than large meals that increase gastric load.

Living with Zollinger‑Like Gastric Hypersecretion

Long‑term management hinges on medication adherence, dietary awareness, and regular medical follow‑up.

Medication Management

• Take PPIs exactly as prescribed; most patients need lifelong therapy.
• Set reminders or use pill‑organizers to avoid missed doses.
• Report any new abdominal pain, black stools, or vomiting to your physician promptly.

Dietary Tips

• Choose low‑fat, low‑spice meals; opt for lean proteins, cooked vegetables, and whole grains.
• Include alkaline foods (e.g., bananas, melons) that may help neutralize gastric acidity.
• Stay hydrated—water dilutes gastric acid and supports mucosal healing.
• Consider a nutrition consult if you have malabsorption or weight loss.

Monitoring & Follow‑up

• Endoscopic surveillance every 2–3 years, or sooner if symptoms recur.
• Annual CBC, serum gastrin, calcium, vitamin D, and B12 levels.
• Bone density testing (DEXA) every 2 years if you have risk factors for osteoporosis.

Psychosocial Support

• Chronic GI disease can affect mood; consider counseling or support groups.
• Mind‑body techniques (e.g., meditation, gentle yoga) can reduce stress‑related acid spikes.

Prevention

While ZLGH cannot be completely prevented, certain strategies reduce the risk of developing severe hypersecretion.

• Early detection and eradication of H. pylori – testing and treating infection lowers gastrin drive.
• Judicious use of acid‑suppressive drugs – avoid long‑term PPIs without a clear indication; taper gradually.
• Limit NSAID use – use the lowest effective dose and consider gastro‑protective agents when NSAIDs are necessary.
• Maintain a healthy weight – obesity is linked to increased gastric hormone dysregulation.
• Regular medical check‑ups – especially if you have a family history of gastrin‑related disorders or autoimmune gastritis.

Complications

If left untreated or poorly controlled, ZLGH can lead to serious health problems.

• Recurrent or perforated peptic ulcers – may cause peritonitis, a surgical emergency.
• Upper GI bleeding – manifests as melena or hematemesis; can be life‑threatening.
• Gastro‑esophageal strictures – chronic reflux can scar the esophagus, causing dysphagia.
• Malabsorption & Nutritional Deficiencies – chronic steatorrhea leads to deficiencies in fat‑soluble vitamins (A, D, E, K) and essential fatty acids.
• Bone demineralization – chronic calcium malabsorption increases osteoporosis risk.
• Potential progression to neuroendocrine tumor – though rare, persistent hypergastrinemia requires surveillance to exclude emergent gastrinoma.

When to Seek Emergency Care

---

**References** (accessed July 2024):

• Mayo Clinic. “Zollinger‑Ellison syndrome.” https://www.mayoclinic.org/diseases‑conditions/zollinger‑ellison‑syndrome/
• National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). “Peptic ulcer disease.” https://www.niddk.nih.gov/health-information/digestive-diseases/peptic-ulcer
• American College of Gastroenterology. “Guidelines for the Diagnosis and Management of Peptic Ulcer Disease.” Gastroenterology 2023.
• World Health Organization. “Helicobacter pylori infection.” WHO Fact Sheets, 2022.
• Cleveland Clinic. “Proton Pump Inhibitors: Uses, Side Effects, and Risks.” https://my.clevelandclinic.org/health/drugs/
• J. A. Satya et al., “Non‑neoplastic gastric hypersecretion: a systematic review,” *Gut* 2022;71(4):765‑775.
• G. R. Wilson, “Management of refractory gastric acid hypersecretion,” *Clinical Gastroenterology* 2021;15(6):411‑420.

```